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Background: The infused autograft lymphocyte-to-monocyte ratio (A-LMR) is a prognostic factor for survival in B-cell
lymphomas post-autologous peripheral hematopoietic stem cell transplantation (APHSCT). Thus, we set out to
investigate if the A-LMR is also a prognostic factor for survival post-APHSCT in T-cell lymphomas.
Methods: From 1998 to 2014, 109 T-cell lymphoma patients that underwent APHSCT were studied. Receiver operating
characteristic (ROC) and area under the curve (AUC) were used to identify the optimal cut-off value of A-LMR for survival
analysis and k-fold cross-validation model to validate the A-LMR cut-off value. Univariate and multivariate Cox proportional
hazard models were used to assess the prognostic discriminator power of A-LMR.
Results: ROC and AUC identified an A-LMR≥ 1 as the best cut-off value and was validated by k-fold cross-validation.
Multivariate analysis showed A-LMR to be an independent prognostic factor for overall survival (OS) and progression-free
survival (PFS). Patients with an A-LMR≥ 1.0 experienced a superior OS and PFS versus patients with an A-LMR < 1.0
[median OS was not reached vs 17.9 months, 5-year OS rates of 87 % (95% confidence interval (CI), 75–94 %) vs 26 %
(95 % CI, 13–42 %), p < 0.0001; median PFS was not reached vs 11.9 months, 5-year PFS rates of 72 % (95 % CI, 58–83 %)
vs 16 % (95 % CI, 6–32 %), p < 0.0001].
Conclusions: A-LMR is also a prognostic factor for clinical outcomes in patients with T-cell lymphomas undergoing
APHSCT.
Keywords: Autograft absolute lymphocyte-to-monocyte count ratio, Survival, Autologous peripheral hematopoietic
stem cell transplantation, T-cell lymphomasIntroduction
The absolute lymphocyte count (ALC), as a surrogate
marker of host immunity, and the absolute monocyte
count (AMC), as a surrogate marker of tumor microenvir-
onment, have been reported to be prognostic factors in
B-cell lymphomas [1–5]. Similarly, recent studies have
shown that both the ALC and AMC have the prognostic
ability to predict clinical outcomes in T-cell lymphomas
[6–8]. In autologous peripheral hematopoietic stem cell
transplantation (APHSCT), day 15 absolute lymphocyte* Correspondence: porrata.luis@mayo.edu
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creativecommons.org/publicdomain/zero/1.0/count (ALC-15) recovery has been associated with im-
proved survival post-transplant not only in B-cell lymph-
omas [9, 10] but also in T-cell lymphomas [11]. ALC-15
recovery directly depends on the amount of autograft ab-
solute lymphocyte count (A-ALC) collected during stem
cell collection and infused in conjunction with stem cells
[12–14]. Furthermore, the day-15 absolute monocyte
count (AMC-15) is also related to the amount of autograft
absolute monocyte count (A-AMC) collected and infused
to patients undergoing APHSCT [15]. Both ALC-15 and
AMC-15 have been reported to affect survival post-
APHSCT [15]. We combined the A-ALC and the A-AMC
as a simple biomarker integrating the host immunityrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Porrata et al. Journal of Hematology & Oncology  (2015) 8:80 Page 2 of 10(i.e., A-ALC) and tumor microenvironment (i.e., A-AMC)
into the autograft lymphocyte-to-monocyte ratio (A-LMR)
and reported that A-LMR directly affects clinical outcomes
in both diffuse large B-cell lymphoma [16] and classical
Hodgkin lymphoma [17] patients undergoing APHSCT.
Thus, we set out to investigate if the A-LMR also affects
survival in T-cell lymphoma patients undergoing APHSCT.
Results
Patients’ characteristics
The median age at the time of transplant for this cohort
of 109 T-cell lymphoma patients was 56 years (range:
19–77 years). The distribution of additional baseline char-
acteristics for these patients is presented in Table 1. The
median follow-up for the entire cohort was 21.5 months
(range: 1–147.8 months) and for the living patients
(N = 70) was 39.6 months (range: 1.8–147.8 months).
Fifty-eight (53 %) of the patients received their APHSCT
up front after finishing induction chemotherapy. Two
patients received SMILE (methotrexate, leucovorin,
ifosfamide, dexamethasone, etoposide, and pegaspargase)
chemotherapy and the rest CHOP (cyclophosphamide,
doxorubicin, vincristine, and prednisone) chemotherapy
as their induction chemotherapy. The salvage chemo-
therapy included CDE, DHAP, and ICE. The day 100
transplant-related mortality (TRM) for the cohort of
patients was 1.8 % (2/109). Thirty-one patients died due
to relapse/progression of lymphoma. Six patients died of
causes unrelated to lymphoma, excluding the two patients
that died in the first 100 days post-APHSCT.
Cut-off values for A-ALC, A-AMC, A-LMR, ALC-15, AMC-15,
and LMR-15 for survival analysis
Receiver operating characteristic (ROC) curves and area
under the curve (AUC) were used to determine the optimal
cut-off points for A-ALC, A-AMC, A-LMR, ALC-15,
AMC-15, and day 15 lymphocyte/monocyte ratio post-
autologous peripheral hematopoietic stem cell transplant-
ation (LMR-15) based on their utility as a marker for the
clinical binary outcome of death/survival. The A-LMR ≥ 1
had an AUC of 0.79 (95 % confidence interval (CI), 0.73–
0.85) with a sensitivity of 70 % (95 % CI, 66–76 %) and
specificity of 87 % (95 % CI, 83–91 %), p < 0.003 (Fig. 1a).
The A-ALC ≥ 0.5 × 109 cells/kg had an AUC of 0.69 (95 %
CI, 0.61–0.77) with a sensitivity of 78 % (95 % CI, 70–
86 %) and specificity of 68 % (95 % CI, 59–77 %), p < 0.04.
The A-AMC< 0.6 × 109 cells/kg had an AUC of 0.71
(95 % CI, 0.62–0.80) with a sensitivity of 64 % (95 % CI,
55–75 %) and specificity of 75 % (95 % CI, 67–83 %), p <
0.0006. The ALC-15 ≥ 500 cells/μl had an AUC of 0.78
(95 % CI, 0.70–0.86) with a sensitivity of 77 % (95 % CI,
69–85 %) and specificity of 78 % (95 % CI, 70–86 %), p <
0.0001. The AMC-15 < 500 cells/μl had an AUC of 0.66
(95 % CI, 0.59–0.73) with a sensitivity of 63 % (95 % CI,54–72 %) and specificity of 84 % (95 % CI, 77–91 %), p <
0.01. The LMR-15 ≥ 1 had an AUC of 0.82 (95 % CI, 0.73–
0.89) with a sensitivity of 75 % (95 % CI, 67–83 %) and
specificity of 81 % (95 % CI, 74–88 %), p < 0.0001. An in-
ternal validation of A-LMR, A-ALC, A-AMC, ALC-15,
AMC-15, and LMR-15 performances as markers for the
clinical binary outcomes of death/survival was performed
using k-fold cross-validation with k = 10. We obtained an
average AUC of 0.80 (95 %CI, 0.73–0.88) over the ten
validation sets for A-LMR with a standard deviation
of ±0.02. We report the ROC for the complete dataset
used in the tenfold procedure, by collecting the A-LMR
obtained on each fold. For A-LMR, the cross-validation
ROC (Fig. 1b) showed an AUC of 0.80 (95 % CI, 0.68–
0.92). The similar areas under the curves from the empir-
ical ROC and the cross-validation ROC, as well as for both
overall survival (OS) (Fig. 2a) and progression-free sur-
vival (PFS) (Fig. 2b) an A-LMR ≥ 1 was the point of
change for the hazard ratio from favorable to unfavorable,
support the use of A-LMR ≥ 1 as the cut-off value as
marker of the binary clinical outcome of death/survival. In
similar fashion, we obtained an average AUC for A-ALC
of 0.67 (95 % CI, 0.59–0.75), A-AMC of 0.68 (95 % CI,
0.60–0.76), ALC-15 of 0.76 (95 % CI, 0.68–0.84), AMC-15
of 0.67 (95 % CI, 0.60–0.74), and LMR-15 of 0.83 (95 %
CI, 0.76–0.90). We report the ROC for the complete
dataset used in the tenfold procedure, by collecting the
A-ALC, A-AMC, ALC-15, AMC-15, and LMR-15 ob-
tained on each fold. For A-ALC, the cross validation
ROC showed an AUC of 0.68 (95 %CI, 0.61–0.75), for
A-AMC of 0.69 (95 % CI, 0.61–0.78), for ALC-15 of
0.77 (95 % CI, 0.69–0.85), for AMC-15 of 0.68 (95 %
CI, 0.61–0.75), and for LMR-15 of 0.84 (95 % CI, 0.77–
0.91). The close values of AUC from the empirical ROC
and the cross-validation ROC support the use of A-
ALC ≥ 0.5 × 109 cells/kg, A-AMC < 0.6 × 109 cells/kg,
ALC-15 ≥ 500 cells/μl, AMC-15 < 500 cells/μl, and
LMR-15 ≥ 1 as the cut-off values to test the binary
clinical outcome of death/survival.Correlation between A-ALC and ALC-15, A-AMC and
AMC-15, and A-LMR and LMR-15
In B-cell lymphomas undergoing APHSCT, we reported
a positive correlation between A-ALC and ALC-15, A-
AMC and AMC-15, and A-LMR and LMR-15. In this
cohort of T-cell lymphoma patients, a strong positive
correlation was also observed between A-ALC and ALC-
15 (R = 0.5, p < 0.0001) (Fig. 3a), between A-AMC and
AMC-15 (R = 0.5, p < 0.0001) (Fig. 3b), and between A-
LMR and LMR-15 (R = 0.7, p < 0.0001) (Fig. 3c). No correl-
ation was identified between the infused CD34 and ALC-15
(R = 0.01, p = 0.9), infused CD34 and AMC-15 (R = 0.13,
p = 0.2), or infused CD34 and LMR-15 (R = 0.10, p = 0.3).








Age, years, median (range) 53 (18–71) 56 (20–75) 0.2
Gender 0.2
Male 38 (64 %) 25 (50 %)
Female 21 (36 %) 25 (50 %)






0 7 (12 %) 6 (12 %)
1 49 (83 %) 34 (68 %)
2 3 (5 %) 10 (20 %)
B symptoms 0.9
Yes 17 (29 %) 15 (30 %)
No 42 (71 %) 35 (70 %)
Stage <0.001
I 2 (3 %) 1 (2 %)
II 26 (44 %) 5 (10 %)
III 9 (15 %) 12 (24 %)
IV 22 (38 %) 32 (64 %)
Bone marrow involvement 0.5
Yes 15 (25 %) 16 (32 %)
No 44 (75 %) 34 (68 %)
Bulky disease 0.8
Yes 3 (5 %) 6 (6 %)














0 13 (22 %) 2 (4 %)
1 19 (32 %) 12 (24 %)
2 17 (29 %) 18 (36 %)
3 8 (13 %) 10 (20 %)
4 1 (2 %) 7 (14 %)
5 1 (2 %) 1 (2 %)
Performance status 0.3
0 7 (12 %) 4 (8 %)
1 45 (76 %) 43 (86 %)
2 5 (8 %) 3 (6 %)
3 2 (45 %) 0 (0 %)
T-cell lymphoma histologies 0.9
Anaplastic large cell 10 (17 %) 5 (13 %)
Table 1 Baseline characteristics in the training set and validation
set (Continued)
Angioimmunoblastic 15 (25 %) 15 (27 %)
Enteropathy-associated 6 (10 %) 3 (6 %)
Hepatosplenic 1 (2 %) 1 (2 %)
NK/T 7 (12 %) 6 (12 %)
Panniculitis 4 (7 %) 3 (6 %)
Peripheral 16 (27 %) 17 (34 %)
IPI factors
Age, years 0.3
60 18 (31 %) 20 (40 %)
≤60 41 (69 %) 30 (60 %)
LDH (U/L) 0.03
Normal 34 (58 %) 18 (36 %)
Abnormal 25 (42 %) 32 (64 %)
Performance status 0.3
1 7 (12 %) 3 (6 %)
≤1 52 (88 %) 47 (94 %)
Extra-nodal disease 0.02
1 3 (5 %) 10 (20 %)
≤1 56 (95 %) 40 (80 %)
Stage <0.001
I/II 28 (47 %) 6 (12 %)
III/IV 31 (53 %) 44 (88 %)
IPI index 0.03
2 10 (17 %) 18 (36 %)
≤2 49 (83 %) 32 (64 %)
Initial chemotherapy 0.9
CHOP 58 (98 %) 49 (98 %)
SMILE 1 (2 %) 1 (2 %)
Salvage chemotherapy (N = 51) 0.2
CDE 2 (9 %) 0 (0 %)
DHAP 5 (21 %) 8 (29 %)
ICE 16 (70 %) 20 (71 %)
Up-front transplant 0.09
Yes 36 (61 %) 22 (44 %)
No 23 (39 %) 28 (56 %)
At transplant
Pre-transplant clinical status <0.001
CR 51 (86 %) 25 (50 %)
PR 8 (15 %) 25 (50 %)
Plerixafor 0.8
Yes 21 (36 %) 19 (38 %)
No 38 (64 %) 31 (62 %)
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Table 1 Baseline characteristics in the training set and validation
set (Continued)
Number of collections 0.08
1 7 (12 %) 12 (24 %)
2 19 (32 %) 15 (30 %)
3 19 (32 %) 9 (18 %)
4 7 (12 %) 11 (22 %)
5 1 (2 %) 2 (4 %)
6 3 (5 %) 0 (0 %)
7 2 (3 %) 0 (0 %)
8 1 (2 %) 1 (2 %)

























Abbreviations: A-ALC autograft absolute lymphocyte count; ALC-15 day 15
absolute lymphocyte count post-autologous peripheral hematopoietic stem cell
transplantation; A-AMC autograft absolute monocyte count; AMC-15 day 15
absolute monocyte count post-autologous peripheral hematopoietic stem
cell transplantation; A-LMR autograft lymphocyte/monocyte ratio; CDE
cyclophosphamide, doxorubicin, and etoposide; CR complete response;
CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone; DHAP
dexamethasone, cytarabine, and cisplatin; ICE ifosfamide, carboplatin, and
etoposide; IPI International Prognostic Index; LDH lactate dehydrogenase;
LMR- 15 day 15 lymphocyte/monocyte ratio post-autologous peripheral
hematopoietic stem cell transplantation; PR partial response; SMILE
methotrexate, leucovorin, ifosfamide, dexamethasone, etoposide, and
pegaspargase
Fig. 1 a Receiver operating characteristics (ROC) curves and area under the
b k-fold cross-validation ROC and AUC for A-LMR in the training set
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Using the univariate Cox regression analysis, the following
variables were predictors for OS: B symptoms, platelets,
extra-nodal disease, lactate dehydrogenase (LDH), stage,
International Prognostic Index (IPI), complete response
(CR) prior to APHSCT, A-ALC, A-AMC, A-LMR, ALC-
15, AMC-15, and LMR-15 (Table 2). For PFS, the fol-
lowing variables were predictors: hemoglobin, platelets,
extra-nodal disease, LDH, stage, IPI, CR prior to APHSCT,
A-ALC, A-AMC, A-LMR, ALC-15, AMC-15, and LMR-15
(Table 2). Since extra-nodal disease, LDH, and stage are
components of IPI, IPI was only included in the multivari-
ate analysis. Multivariate analysis identified the following
predictors for OS and PFS: A-ALC, A-LMR, A-AMC, and
CR prior to APHSCT (Table 3). To avoid the problem of
colinearity due to the strong positive correlation between
A-ALC and ALC-15, A-AMC and AMC-15, and A-LMR
and LMR-15, we substituted ALC-15 for A-ALC, AMC-15
for A-AMC, and LMR-15 for A-LMR and tested them
against the other predictors (CR prior to APHSCT, extra-
nodal disease, hemoglobin, IPI, LDH, platelets, and stage)
in the multivariate analysis. ALC-15, AMC-15, and LMR-
15 remained independent predictors for OS and PFS:
for OS [ALC-15: hazard ratio (HR) of 0.256, 95 % CI,
0.094–0.665, p < 0.005; AMC-15: HR of 0.351, 95 % CI,
0.169–0.820, p < 0.01; and LMR-15: HR of 0.307, 95 %
CI, 0.102–0.820, p < 0.02] and for PFS [ALC-15: HR of
0.439, 95 % CI, 0.200–0.967, p < 0.04; AMC-15: HR of
0.383, 95 % CI, 0.175–0.867, p < 0.01; and LMR-15: HR
of 0.408, 95 % CI, 0.200–0.823, p < 0.01].
Survival outcomes based on A-LMR
Using the cut-off value of 1.0 for the A-LMR obtained from
the empiric ROC and subsequently validated by k-fold
cross-validation, we tested A-LMR ≥ 1 for OS and PFS. Wecurve (AUC) for autograft lymphocyte-to-monocyte ratio (A-LMR).
Fig. 2 a Determination of hazard ratio associated with different levels of autograft lymphocyte-to-monocyte ratio (A-LMR) as a continuous variable for
overall survival. b Determination of hazard ratio associated with different levels of A-LMR as continuous variable for progression-free survival
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pared with patients infused with an A-LMR < 1 experienced
superior OS (Fig. 4a) and PFS (Fig. 4b) [median OS was not
reached versus 17.9 months, 5-year OS rates of 87 % (95 %
CI, 75–94 %) versus 26 % (95 % CI, 13 %-42 %), p < 0.0001;
median PFS was not reached versus 11.9 months, 5-year
PFS rates of 72 % (95 % CI, 58–83 %) versus 16 % (95 % CI,
6–32 %), p < 0.0001]. By histopathological subtype, superior
OS and PFS was observed in patients with an A-LMR ≥ 1
compared with patients with an A-LMR < 1 diagnosed with
peripheral T-cell lymphoma not otherwise specified (NOS)
[median OS (Fig. 5a) was not reached versus 18.7 months,
3-year OS rates of 79 % (95 % CI, 70–93 %) versus 46 %
(95 % CI, 23–71 %), p < 0.05; median PFS (Fig. 5b) was not
reached versus 12.2 months, 3-year PFS rates of 60 % (95 %
CI, 51–91 %) versus 21 % (95 % CI, 7–47 %), p < 0.0001],
for angioimmunoblastic T-cell lymphoma [median OS
(Fig. 5c) was not reached versus 14.6 months, 3-year
OS rates of 92 % (95 % CI, 59–99 %) versus 24 % (95 %
CI, 8–54 %), p < 0.0001; median PFS (Fig. 5d) was not
reached versus 11.9 months, 3-year PFS rates of 78 %
(95 % CI, 48–93 %) versus 0 %, p < 0.0001], and for
others [median OS (Fig. 5e) was not reached versus
18.1 months, 3-year OS rates of 88 % (95 % CI, 70–
96 %) versus 28 % (95 % CI, 10–57 %), p < 0.05; median
PFS (Fig. 5f ) was not reached versus 5.3 months, 3-year
PFS rates of 74 % (95 % CI, 64–94 %) versus 28 % (95 %
CI, 12–54 %), p < 0.0001].Discussion
In B-cell lymphoma, the A-LMR has been reported to
be a prognostic factor for survival in patients treated
with APHSCT. Thus, we set out to investigate if the
A-LMR can impact survival in patients with T-cell
lymphomas treated with APHSCT.
In all T-cell lymphoma patients undergoing APHSCT,
the infusion of an A-LMR ≥ 1 was associated with super-
ior OS and PFS. Furthermore, A-LMR showed a homo-
geneous prognostic role between the histological subtypes,
as superior survival was observed in patients with an
infused A-LMR ≥ 1 regardless of the underlying T-cell
lymphoma histologies. This observation was observed
in subsets of patients categorized by histological sub-
types as well. Multivariate analysis revealed the A-LMR
to be an independent prognostic factor for survival in
T-cell lymphoma patients treated with APHSCT when
adjusted for other reported prognostic factors.
The ALC-15 has been reported to be a prognostic
factor for survival in B-cell lymphomas treated with
APHSCT and has also been reported to be a prognostic
factor for survival in T-cell lymphoma patients undergoing
APHSCT. The ALC-15 recovery is directly dependent on
the amount of collected and infused A-ALC. In this study,
as we published in B-cell lymphomas [12], the correlation
between A-ALC and ALC-15 was confirmed for the first
time in T-cell lymphomas treated with APHSCT. In vitro
and clinical studies have reported inhibition of host
Fig. 3 Scatter plots for: a autograft absolute lymphocyte count (A-ALC) and day 15 absolute lymphocyte count (ALC-15), b autograft absolute
monocyte count (A-AMC) and day 15 absolute monocyte count (AMC-15), and c autograft absolute lymphocyte/monocyte ration (A-LMR) and
day 15 absolute lymphocyte/monocyte ratio (LMR-15)
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cytes in T-cell lymphoma [18]. In APHSCT, we docu-
mented that A-AMC, which directly affects AMC-15
recovery, conveyed a negative prognosis in B-cell lymph-
omas. We observed the same negative survival effect in
T-cell lymphoma patients infused with higher A-AMC
and AMC-15 numbers post-APHSCT. As in our previ-
ous reports [12, 13, 15], no correlation was identified
between the infused CD34 count and ALC-15, AMC-15,
or LMR-15 in T-cell lymphoma patients undergoing
APHSCT. To our knowledge, this is the first study
reporting that the A-LMR, which combined the bio-
markers of A-ALC and A-AMC, not only affects ALC-15
and AMC-15 recovery but also survival in T-cell lymph-
oma patients treated with APHSCT. The possible mech-
anism addressing the negative survival of patients infused
with an A-LMR < 1 due to the higher content of A-AMC
has been addressed in our previous publication [19].The limitations of our study include being a retro-
spective study and a small cohort of T-cell lymphomas
undergoing APHSCT. The strengths of the study in-
clude long-term follow-up of T-cell lymphoma patients
treated consecutively with APHSCT at a single institu-
tion. This study expands on the previous publications
regarding A-ALC and A-AMC by highlighting the im-
portance of the interaction between host immunity and
tumor microenvironment, using the simple biomarkers
of A-ALC and A-AMC combined in the prognostic fac-
tor of A-LMR.Conclusion
Finally, the association between A-LMR and survival
provides a rationale to develop clinical translational in-
terventions to engineer immunocompetent autografts with
direct impact on immune recovery and survival, not only in
Table 2 Univariate analysis for overall survival (OS) and progression-free survival (PFS)
Variable OS PFS
HR 95 % CI p HR 95 % CI p
Age > 60 years 1.532 0.784–2.900 0.2 1.400 0.789–2.422 0.2
Female versus male 1.153 0.606–2.170 0.7 1.359 0.787–2.342 0.3
B symptoms 1.919 1.094–3.615 0.05 1.425 0.790–2.485 0.2
Bulky disease 1.007 0.164–3.294 0.9 1.109 0.270–3.024 0.9
Hemoglobin < 12.0 g/dl 1.636 0.862–3.072 0.1 1.858 1.076–3.193 0.03
Platelet < 150 × 109/l 2.566 1.312–4.862 0.007 2.890 1.671–5.047 <0.001
Extra-nodal sites > 1 3.043 1.354–6.197 0.009 2.332 1.104–4.470 0.03
LDH (U/L) 6.695 3.001–17.77 <0.001 4.510 2.440–8.989 <0.001
Performance status > 1 1.788 0.674–3.972 0.2 2.033 0.885–4.089 0.09
Stage III/IV 3.817 1.630–11.160 <0.001 2.571 1.393–5.431 0.004
IPI > 2 4.442 2.342–8.459 <0.001 3.734 2.146–6.444 <0.001
Positive bone marrow 1.670 0.856–3.153 0.1 1.294 0.709–2.271 0.4
Infused CD34 0.893 0.758–1.032 0.1 0.950 0.832–1.070 0.4
CR prior to APHSCT 0.164 0.081–0.314 <0.001 0.186 0.106–0.321 <0.001
A-ALC≥ 0.5 × 109/kg 0.358 0.188–0.676 0.002 0.294 0.167–0.511 <0.001
A-AMC≥ 0.6 × 109/kg 3.207 1.585–7.175 <0.001 2.254 1.285–4.116 0.004
A-LMR≥ 1 0.155 0.066–0.322 <0.001 0.196 0.104–0.353 <0.001
ALC-15≥ 0.5 cells/μl 0.158 0.072–0.304 <0.001 0.246 0.139–0.430 <0.001
AMC-15≥ 0.5 cells/μl 3.909 1.881–9.160 <0.001 2.645 1.489–4.918 <0.001
LMR-15 0.143 0.061–0.497 <0.001 0.214 0.116–0.378 <0.001
Plerixafor 0.954 0.497–1.925 0.7 0.886 0.510–1.587 0.8
Abbreviations: A-ALC autograft absolute lymphocyte count, ALC-15 day 15 absolute lymphocyte count post-autologous peripheral hematopoietic stem cell transplantation,
A-AMC autograft absolute monocyte count, AMC-15 day 15 absolute monocyte count post-autologous peripheral hematopoietic stem cell transplantation, A-LMR autograft
lymphocyte/monocyte ratio, LMR-15 day 15 lymphocyte/monocyte ratio post-autologous peripheral hematopoietic stem cell transplantation, CR complete response, IPI
International Prognostic Index, LDH lactate dehydrogenase




To qualify for the study, patients were required to be
candidates for APHSCT with the diagnosis of T-cell
lymphoma and have mobilized enough peripheral bloodTable 3 Multivariate analysis for overall survival (OS) and progressio
Variable OS
HR 95 % CI
A-ALC≥ 0.5 × 109/kg 0.401 0.231–0.972
A-AMC < 0.6 × 109/kg 0.502 0.100–0.985
A-LMR≥ 1 0.258 0.105–0.561
CR prior to APHSCT 0.356 0.166–0.731
Hemoglobin < 12 g/dl
IPI > 2 2.377 1.163–4.972
Platelet < 150 × 109/l 1.297 0.627–2.607
Abbreviations: A-ALC autograft absolute lymphocyte count, A-AMC autograft absolu
autograft lymphocyte/monocyte ratio, CR complete response, IPI International Progstem cells to proceed with APHSCT (minimum of 2.0 ×
106 CD34 cells/kg). Patients were excluded if they failed
to mobilize stem cells, required bone marrow harvest,
were infused with both peripheral blood and bone-
marrow-harvest-derived stem cells, or participated in
stem cell transplantation clinical trials. No patients were
lost to follow-up. From 1998 to 2014, 109 T-cell lymph-
oma patients qualified for the study. All patients gaven-free survival (PFS)
PFS
p HR 95 % CI p
0.04 0.439 0.271–0.902 0.03
0.04 0.490 0.288–0.911 0.03
<0.001 0.298 0.112–0.482 <0.001
0.005 0.401 0.211–0.681 0.008
1.592 0.861–2.935 0.1
0.02 1.398 0.705–2.771 0.3
0.5 1.164 0.590–2.268 0.7
te monocyte count, A-LMR autograft lymphocyte/monocyte ratio, A-LMR
nostic Index, LDH lactate dehydrogenase
Fig. 4 a Overall survival based on autograft lymphocyte-to-monocyte ratio (A-LMR). b Progression-free survival based on autograft lymphocyte-to-
monocyte ratio (A-LMR)
Fig. 5 Overall survival: a peripheral T-cell lymphoma, c angioimmunoblastic T-cell lymphoma, and e others. Progression-free survival: b peripheral
T-cell lymphoma, d angioimmunoblastic T-cell lymphoma, and f others
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medical records for medical research. Approval for the
retrospective review of these records was obtained from
the Mayo Clinic Institutional Review Board and was in ac-
cordance with US federal regulations and the Declaration
of Helsinki.
End points
The primary end point of the study was to assess the im-
pact of A-LMR on overall survival (OS) and progression-
free survival (PFS) from the time of APHSCT in patients
with T-cell lymphoma. The infused A-ALC for each
apheresed unit collection was calculated as follows:
A-ALC = % collection lymphocytes × (absolute white
blood cell (WBC) count/kg). The infused A-AMC for
each apheresed unit collection was calculated as follows: A-
AMC=% collection monocytes × (absolute WBC count/kg).
The A-LMR was then calculated by dividing the A-ALC by
the A-AMC.
Prognostic factors
The following prognostic factors were evaluated in the
study: international prognostic score (IPI) [20] at diagnosis:
[age (>60 years), extra-nodal disease (>1 site), lactate
dehydrogenase (LDH), performance status (>1), and stage];
A-LMR; A-ALC; A-AMC; ALC-15; AMC-15; day 15
lymphocyte-to monocyte ratio (LMR-15); B symptoms;
bone marrow involvement at diagnosis; bulky disease
(>10 cm); clinical status prior to APHSCT [complete
response (CR) versus partial response (PR)]; hemoglobin
(<12 g/dl) at diagnosis; platelets (<150 × 109/l) at diagno-
sis; and infused CD34+ stem cells dose.
Peripheral blood stem cell (autograft) collections
Patients received granulocyte colony-stimulating factor
(G-CSF) for mobilization at a dose of 10 μg/kg daily for
5–7 consecutive days by subcutaneous injection. Once
the peripheral blood CD34+ cell count was ≥10 cells/μl
on G-CSF, patients began daily apheresis until a minimum
target of 2.0 × 106 CD34 cells/kg was reached. If on day 4
on G-CSF, the peripheral blood CD34 was less than
10 cells/μl, the addition of plerixafor 0.24 mg/kg was
allowed.
Conditioning regimen
All patients were treated with BEAM: BCNU (300 mg/m2)
on day −6, etoposide (100 mg/m2) twice daily from
days −5 to −2, cytarabine (100 mg/m2) twice daily from
days −5 to −2, and melphalan (140 mg/m2) on day −1.
Response and survival
Response criteria were based on the guidelines from the
International Harmonization Project on Lymphoma [21].
OS was measured from the date of transplant to the dateof death or last follow-up. PFS was defined as the time
from transplant to the time of progression, relapse,
death, or last follow-up.Statistical analysis
OS and PFS were analyzed using the approach of Kaplan
and Meier [22]. Differences between survival curves were
tested for statistical significance using the two-tailed log-
rank test. The Cox proportional hazard model [23] was
used for the univariate and multivariate analyses to evalu-
ate the variables under the “Prognostic factors” section
to assess their impact on post-APSCHT OS and PFS
times. The choice of optimal cut-off for A-LMR, A-ALC,
A-AMC, ALC-15, AMC-15, and LMR-15 to assess sur-
vival was based on their utility as a marker for the clinic-
ally relevant binary outcome of death/survival using the
receiver operating characteristic (ROC) curves and area
under the curve (AUC). The binary clinical outcome
(death/survival) was established at 5 years post-APHSCT.
Patients were classified as “alive/censored” when follow-
up time was greater than 5 years and “death” for patients
known to have died before this time point [24]. A k-fold
cross-validation with k values of 10 was performed to
validate the results of A-LMR, A-ALC, A-AMC, ALC-15,
AMC-15, and LMR-15. Based on this analysis, cross-
validation AUC by the ROC was produced, representing
the discriminating accuracy of A-LMR, A-ALC, A-AMC,
ALC-15, AMC-15, and LMR-15 for the binary clinical
outcomes of death/survival. To assess the reproducibility
of the cut-off value for A-LMR obtained by the ROC
curves, the relationship between A-LMR as a continuous
variable and the logarithm of the hazard ratio was ex-
plored using the Cox proportional hazard restricted
cubic spline regression in regard to OS and PFS. The
cut-off value was chosen at the point where the A-LMR
value caused the hazard ratio to change from favorable
to unfavorable.
Χ2 tests and Fisher exact tests were used to determine
relationships between categorical variables as appropriate.
The Wilcoxon rank test was used to determine associa-
tions between continuous variables and categories, and
nonparametric tests were used to evaluate associations for
continuous variables. All p values represented were two-
sided, and statistical significance was declared at p < 0.05.
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